Physician profile
Gregory D Groth
NPI 1124072855
$744.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $43.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.92 | 2021 | |
| Sunovion Pharmaceuticals INC. | $58.03 | 2021 | |
| Vanda Pharmaceuticals INC. | $48.29 | 2021 | |
| Bausch Health US, LLC | $44.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.66 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $39.84 | 2021 | |
| Lundbeck LLC | $30.43 | 2021 | |
| Supernus Pharmaceuticals, INC. | $27.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.62 | 2021 | |
| Alkermes, INC. | $22.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.47 | 2021 | |
| Almatica Pharma LLC | $11.48 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Groth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.